Chia Tai Bioscience (300122.SZ): Quadrivalent influenza virus split vaccine (ZFA02 adjuvant) enters phase I/II clinical trials.

Zhitong Finance and Economics APP News, Zhifei Biology (300122.SZ) announced that its wholly-owned subsidiary Anhui Zhifeilongke Ma Biological Pharmaceuticals Co., Ltd. (referred to as "Zhifeilongke Ma") has conducted Phase I/II clinical trials of the four-valent influenza virus split lytic vaccine (ZFA02 adjuvant) (referred to as "adjuvant quadrivalent influenza vaccine") in Hebei Province.